|
|
|
Intercure Ltd (NASDAQ: INCR) |
|
Intercure Ltd
INCR's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Intercure Ltd 's sales fell
by -8.52 % in IV. Quarter 2023 from the same quarter a year ago.
Ranking at No. 2438
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Intercure Ltd faced net loss in contrast to the net income a year ago in IV. Quarter 2023
• More on INCR's Growth
|
|
Intercure Ltd
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.29 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 0.19.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.19.
• More on INCR's Valuation
|
|
|
|
|
Intercure Ltd
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.29 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 0.19.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.19.
Intercure Ltd Price to Book Ratio is at 0.15 lower than Industry Avg. of 78.62. and higher than S&P 500 Avg. of 0.01
• More on INCR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
